Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13656758 | 1.00 | SRD5A1 (0.64) | SRD5A1SRD5A2 | |
| SCHEMBL7751282 | 1.00 | SRD5A1 (0.64) | SRD5A1SRD5A2 | |
| SCHEMBL4265528 | 1.00 | SRD5A1 (0.64) | SRD5A1SRD5A2 | |
| SCHEMBL14046283 | 0.85 | SRD5A1 (0.65) | SRD5A1SRD5A2 | |
| SCHEMBL8073983 | 0.84 | SRD5A1 (0.67) | SRD5A1SRD5A2 | |
| SCHEMBL8071826 | 0.84 | SRD5A1 (0.67) | SRD5A1SRD5A2 | |
| SCHEMBL8939853 | 0.84 | SRD5A1 (0.55) | SRD5A1SRD5A2 | |
| SCHEMBL13604091 | 0.84 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL4187752 | 0.84 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL9571051 | 0.84 | SRD5A1 (0.72) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467739-A4 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | claimed |
| US-20050107416-A1 | 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-05-19 | — | — | US | claimed |
| EP-1467739-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-10-20 | — | — | EP | claimed |
| WO-2003059293-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-07-24 | — | — | WO | claimed |
| US-7605152-B2 | 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1467739-A4 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20050107416-A1 | 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-05-19 | — | — | US | disclosed |
| EP-1467739-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003059293-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-0880540-B1 | 17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE | AVENTIS PHARMA INC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6365597-B1 | FOR THERAPY OF ANDROGEN AND ESTROGEN MEDIATED DISORDERS, INCLUDING BENIGN PROSTATIC HYPERPLASIA, ANDROGEN MEDIATED PROSTATE CANCER, ESTROGEN MEDIATED BREAST CANCER AND ACNE | AVENTIS PHARMACEUTICALS INC. | 2002-04-02 | — | — | US | disclosed |
| EP-0649306-B1 | ESTER DERIVATIVES OF 4-AZA-STEROIDS | MERCK & CO INC (US) | 2001-01-10 | — | — | EP | disclosed |
| US-5494914-A | USEFUL FOR TREATMENT OF DISEASES WHOSE PROGRESS IS AIDED BY ACTIVATION OF ANDROGEN RECEPTORS | ENDORECHERCHE (CA) | 1996-02-27 | — | — | US | disclosed |
| EP-0641204-A4 | 17-ETHERS AND THIOETHERS OF 4-AZA-STEROIDS. | MERCK & CO INC (US) | 1995-08-23 | — | — | EP | disclosed |
| EP-0650495-A1 | IMPROVED ANTIANDROGENS | ENDORECHERCHE INC. (CA) | 1995-05-03 | — | — | EP | disclosed |
| EP-0641204-A1 | 17-ETHERS AND THIOETHERS OF 4-AZA-STEROIDS | MERCK & CO. INC. (US) | 1995-03-08 | — | — | EP | disclosed |
| EP-0641211-A1 | INHIBITORS OF TESTOSTERONE 5$g(a)-REDUCTASE ACTIVITY | ENDORECHERCHE INC. (CA) | 1995-03-08 | — | — | EP | disclosed |
| WO-1994026767-A1 | IMPROVED ANTIANDROGENS | ENDORECHERCHE INC. (CA) | 1994-11-24 | — | — | WO | disclosed |
| EP-0572166-A1 | New 7beta-substituted-4-aza-5a-androstan-3-ones as 5a-reductase inhibitors | MERCK & CO. INC. (US) | 1993-12-01 | — | — | EP | disclosed |
| WO-1993023053-A1 | INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY | ENDORECHERCHE INC. (CA) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107416-A1 | 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators | SHBG, CYP19A1, NR5A1 | SRD5A1 5/4885SRD5A2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.